GlassScriptPhysician profile
Edward Barbarito
NPI 1174503148
$13,136.26
in general payments reported to CMS, 2019-2025
32 companies · $2,419 in 2025
The $2,419 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,310 · 2020: $1,908 · 2021: $395 · 2022: $363 · 2023: $1,048 · 2024: $1,692 · 2025: $2,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,159.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,723.05 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,616.15 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Qol Medical, LLC | $1,467.84 | 2019-2023 | Sucraid |
| Janssen Biotech, INC. | $567.60 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $555.33 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $324.22 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $290.33 | 2023-2025 | Ibsrela |
| Celgene Corporation | $248.85 | 2022-2024 | Zeposia |
| Pfizer INC. | $242.16 | 2019-2025 | |
| Madrigal Pharmaceuticals | $231.52 | 2025 | Rezdiffra |
| Vivus LLC | $217.28 | 2023-2025 | Qsymia, Pancreaze |
| Aimmune Therapeutics, INC. | $166.11 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $161.17 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $139.29 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $126.21 | 2019-2025 | Sutab, Suflave |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $124.63 | 2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $98.63 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $98.04 | 2020-2025 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $88.16 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $81.75 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $81.20 | 2019-2025 | Linzess |
| Boston Scientific Corporation | $79.01 | 2023-2024 | |
| Gilead Sciences, INC. | $78.16 | 2020-2025 | |
| Medtronic, INC. | $56.62 | 2023 | Gi Genius |
| Evoke Pharma, INC. | $53.58 | 2025 | |
| Allergan, INC. | $51.31 | 2019 | |
| Nestle Healthcare Nutrition INC. | $43.95 | 2021-2023 | |
| Concordia Pharmaceuticals INC. | $35.15 | 2019 | |
| Redhill Biopharma INC. | $31.55 | 2020 | |
| Genzyme Corporation | $21.64 | 2023 | |
| Olympus America INC. | $20.81 | 2019 | |
| Daiichi Sankyo INC. | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Barbarito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.